Journal article
Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
Haematologica (Roma), Vol.103(2), pp.297-303
02/2018
DOI: 10.3324/haematol.2017.176511
PMCID: PMC5792274
PMID: 29170255
Abstract
The prevalence, presenting clinical and pathological characteristics, and outcomes for patients with diffuse large B-cell lymphoma that is Epstein-Barr virus positive remain uncertain as does the impact of congenital or iatrogenic immunosuppression. Patients with newly diagnosed diffuse large B-cell lymphoma with available tissue arrays were identified from the University of Iowa/Mayo Clinic Molecular Epidemiology Resource. Patients infected with human immunodeficiency virus or who had undergone a prior organ transplant were excluded. Epstein-Barr virus-associated ribonucleic acid testing was performed on all tissue arrays. A history of significant congenital or iatrogenic immunosuppression was determined for all patients. At enrollment, 16 of the 362 (4.4%) biopsies were positive for Epstein-Barr virus. Thirty-nine (10.8%) patients had a significant history of immunosuppression. Patients with Epstein-Barr-positive diffuse large B-cell lymphoma had no unique clinical characteristics but on pathology exhibited a higher frequency of CD30 positivity (25.0%
8.1%, respectively;
<0.01), and non-germinal-center subtype (62.5%
34.1%, respectively;
<0.01). No baseline clinical characteristics were associated with a history of immunosuppression. With a median follow up of 59 months, and after adjustment for International Prognostic Index, there was no association of Epstein-Barr virus positivity or immunosuppression with event-free survival at 24 months (odds ratio=0.49; 95% confidence interval: 0.13-1.84 and odds ratio=0.81; 95% confidence interval: 0.37-1.77) or overall survival (hazard ratio=0.86; 95% confidence interval: 0.38-1.97 and hazard ratio=1.00; 95% confidence interval: 0.57-1.74). In contrast to non-Western populations, our North American population had a low prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma that did not convey an adverse prognosis. A history of immunosuppression, while known to be a risk factor for the development of diffuse large B-cell lymphoma, did not affect subsequent prognosis.
Details
- Title: Subtitle
- Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression
- Creators
- Sean I Tracy - Mayo Clinic, Rochester, MN, USAThomas M Habermann - Mayo Clinic, Rochester, MN, USAAndrew L Feldman - Mayo Clinic, Rochester, MN, USAMatthew J Maurer - Mayo Clinic, Rochester, MN, USAAhmet Dogan - Memorial Sloan Kettering Cancer Center, New York, NY, USAUsha S Perepu - University of Iowa, Iowa City, IA, USASergei Syrbu - University of Iowa, Iowa City, IA, USAStephen M Ansell - Mayo Clinic, Rochester, MN, USACarrie A Thompson - Mayo Clinic, Rochester, MN, USAGeorge J Weiner - University of Iowa, Iowa City, IA, USAGrzegorz S Nowakowski - Mayo Clinic, Rochester, MN, USACristine Allmer - Mayo Clinic, Rochester, MN, USASusan L Slager - Mayo Clinic, Rochester, MN, USAThomas E Witzig - Mayo Clinic, Rochester, MN, USAJames R Cerhan - Mayo Clinic, Rochester, MN, USABrian K Link - University of Iowa, Iowa City, IA, USA brian-link@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Haematologica (Roma), Vol.103(2), pp.297-303
- Publisher
- Italy
- DOI
- 10.3324/haematol.2017.176511
- PMID
- 29170255
- PMCID
- PMC5792274
- ISSN
- 0390-6078
- eISSN
- 1592-8721
- Grant note
- U01 CA195568 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
- Language
- English
- Date published
- 02/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Pharmaceutical Sciences and Experimental Therapeutics; Chemical and Biochemical Engineering; Internal Medicine
- Record Identifier
- 9984047732202771
Metrics
14 Record Views